HM Payson & Co. Increases Stock Position in Eli Lilly and Company (NYSE:LLY)

HM Payson & Co. lifted its holdings in Eli Lilly and Company (NYSE:LLY) by 1.8% during the third quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 21,953 shares of the company’s stock after buying an additional 378 shares during the quarter. HM Payson & Co.’s holdings in Eli Lilly and Company were worth $19,449,000 as of its most recent SEC filing.

Other institutional investors also recently modified their holdings of the company. M&G Plc bought a new position in shares of Eli Lilly and Company during the first quarter valued at approximately $8,896,000. Virtu Financial LLC purchased a new position in Eli Lilly and Company during the first quarter valued at $2,138,000. China Universal Asset Management Co. Ltd. boosted its holdings in Eli Lilly and Company by 19.6% in the first quarter. China Universal Asset Management Co. Ltd. now owns 9,897 shares of the company’s stock worth $7,699,000 after acquiring an additional 1,620 shares in the last quarter. Mutual Advisors LLC boosted its holdings in Eli Lilly and Company by 404.8% in the first quarter. Mutual Advisors LLC now owns 62,598 shares of the company’s stock worth $48,699,000 after acquiring an additional 50,197 shares in the last quarter. Finally, Private Advisor Group LLC grew its stake in shares of Eli Lilly and Company by 0.6% in the first quarter. Private Advisor Group LLC now owns 76,282 shares of the company’s stock worth $59,345,000 after acquiring an additional 430 shares during the last quarter. 82.53% of the stock is currently owned by institutional investors.

Eli Lilly and Company Trading Down 2.0 %

Shares of Eli Lilly and Company stock opened at $829.84 on Friday. Eli Lilly and Company has a 1-year low of $547.61 and a 1-year high of $972.53. The company’s fifty day simple moving average is $913.71 and its 200-day simple moving average is $864.86. The company has a debt-to-equity ratio of 1.74, a current ratio of 1.11 and a quick ratio of 0.87. The stock has a market capitalization of $788.70 billion, a PE ratio of 89.71, a P/E/G ratio of 3.07 and a beta of 0.42.

Eli Lilly and Company (NYSE:LLY) last released its quarterly earnings results on Wednesday, October 30th. The company reported $1.18 earnings per share (EPS) for the quarter, missing the consensus estimate of $1.52 by ($0.34). The company had revenue of $11.44 billion for the quarter, compared to the consensus estimate of $12.09 billion. Eli Lilly and Company had a net margin of 20.48% and a return on equity of 73.73%. The business’s revenue for the quarter was up 20.4% on a year-over-year basis. During the same period in the prior year, the firm posted $0.10 EPS. As a group, equities analysts anticipate that Eli Lilly and Company will post 13.79 earnings per share for the current year.

Eli Lilly and Company Announces Dividend

The company also recently announced a quarterly dividend, which will be paid on Tuesday, December 10th. Investors of record on Friday, November 15th will be issued a $1.30 dividend. This represents a $5.20 annualized dividend and a yield of 0.63%. The ex-dividend date is Friday, November 15th. Eli Lilly and Company’s dividend payout ratio is 56.22%.

Analyst Ratings Changes

Several equities analysts have recently issued reports on the company. Guggenheim lifted their price target on Eli Lilly and Company from $884.00 to $1,030.00 and gave the stock a “buy” rating in a research report on Friday, August 16th. JPMorgan Chase & Co. lifted their target price on shares of Eli Lilly and Company from $1,050.00 to $1,100.00 and gave the stock an “overweight” rating in a report on Friday, September 13th. Deutsche Bank Aktiengesellschaft reiterated a “buy” rating and set a $1,025.00 price target on shares of Eli Lilly and Company in a report on Thursday, October 3rd. BMO Capital Markets boosted their price objective on shares of Eli Lilly and Company from $1,001.00 to $1,101.00 and gave the stock an “outperform” rating in a report on Friday, August 9th. Finally, Evercore ISI raised Eli Lilly and Company to a “hold” rating in a research report on Thursday, September 5th. Three equities research analysts have rated the stock with a hold rating and seventeen have assigned a buy rating to the company. According to MarketBeat, the stock presently has an average rating of “Moderate Buy” and an average price target of $1,009.00.

Eli Lilly and Company Company Profile

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity.